A Therapeutic Peptide Vaccine Against PCSK9.

A Therapeutic Peptide Vaccine Against PCSK9.
复制标题

一种针对 PCSK9 的治疗性肽疫苗

DOI:
10.1038/s41598-017-13069-w
复制
发表时间:
2017-10-02
期刊:
影响因子:
4.6
通讯作者:
Liao Y
Liao Y
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Pan Y;Zhou Y;Wu H;Chen X;Hu X;Zhang H;Zhou Z;Qiu Z;Liao Y

文献摘要

参考文献

被引文献

相似文献

疫苗接种为高胆固醇血症的治疗及提高患者依从性提供了一种有前景的方法。在本研究中,对靶向前蛋白转化酶枯草溶菌素9型(PCSK9)的合适病毒样颗粒(VLP) - 肽疫苗进行了筛选。目标肽的筛选标准如下:(1)位于PCSK9的催化结构域,或对PCSK9与低密度脂蛋白受体(LDLR)的结合起调节作用;(2)与宿主蛋白质组比对时相似度低或无相似度;(3)具备理想的抗原性和亲水性;(4)包含PCSK9的功能性突变位点。研究发现,接种VLP - PCSK9肽疫苗,尤其是PCSK9Qβ - 003疫苗的小鼠,产生了针对PCSK9的高滴度IgG抗体。PCSK9Qβ - 003疫苗显著降低了Balb/c小鼠和LDLR +/−小鼠的血浆总胆固醇水平。此外,PCSK9Qβ - 003疫苗降低了血浆PCSK9水平,并上调了肝脏中LDLR的表达。另外,在LDLR +/−小鼠中,注射PCSK9Qβ - 003疫苗与固醇调节元件结合蛋白2(SREBP - 2)、肝细胞核因子1α(HNF - 1α)以及3 - 羟基 - 3 - 甲基戊二酰辅酶A(HMG - CoA)还原酶的显著上调相关。在接种疫苗的动物中未检测到明显的免疫损伤。因此,PCSK9Qβ - 003疫苗可能是一种颇具吸引力的通过降低胆固醇和调节脂质稳态来治疗高胆固醇血症的方法。
Vaccination provides a promising approach for treatment of hypercholesterolemia and improvement in compliance. In this study, the appropriate virus-like particle (VLP)-peptide vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) were screened. The screening criteria of target peptides were as follows: (1) located in catalytic domain of PCSK9, or regulating the binding of PCSK9 and LDL receptors (LDLR); (2) having low/no-similarity when matched with the host proteome; (3) possessing ideal antigenicity and hydrophilicity; (4) including the functional mutation site of PCSK9. It was found that mice vaccinated with VLP -PCSK9 peptide vaccines, especially PCSK9Qβ-003 vaccine, developed high titer IgG antibodies against PCSK9. PCSK9Qβ-003 vaccine obviously decreased plasma total cholesterol in both Balb/c mice and LDLR+/−mice. Also, PCSK9Qβ-003 vaccine decreased plasma PCSK9 level and up-regulated LDLR expression in liver. Additionally, PCSK9Qβ-003 vaccine injection was associated with significant up-regulation of sterol-regulatory element-binding protein-2 (SREBP-2), hepatocyte nuclear factor 1α (HNF-1α), and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in LDLR+/−mice. No obvious immune injury was detected in vaccinated animals. The PCSK9Qβ-003 vaccine, therefore, may be an attractive treatment approach for hypercholesterolemia through decreasing cholesterol and regulating lipid homeostasis.
1 型血管紧张素受体疫苗可预防链脲佐菌素诱发的糖尿病肾病
DOI: 10.1007/s00109-015-1343-6
发表时间: 2016-02
期刊: Journal of molecular medicine (Berlin, Germany)
影响因子: --
作者:
Ding D;Du Y;Qiu Z;Yan S;Chen F;Wang M;Yang S;Zhou Y;Hu X;Deng Y;Wang S;Wang L;Zhang H;Wu H;Yu X;Zhou Z;Liao Y;Chen X
通讯作者: Chen X
DOI: 10.7150/ijbs.3524
发表时间: 2012
影响因子: 9.2
作者:
Zhang L;McCabe T;Condra JH;Ni YG;Peterson LB;Wang W;Strack AM;Wang F;Pandit S;Hammond H;Wood D;Lewis D;Rosa R;Mendoza V;Cumiskey AM;Johns DG;Hansen BC;Shen X;Geoghagen N;Jensen K;Zhu L;Wietecha K;Wisniewski D;Huang L;Zhao JZ;Ernst R;Hampton R;Haytko P;Ansbro F;Chilewski S;Chin J;Mitnaul LJ;Pellacani A;Sparrow CP;An Z;Strohl W;Hubbard B;Plump AS;Blom D;Sitlani A
通讯作者: Sitlani A
DOI: 10.1194/jlr.m003566
发表时间: 2010-06-01
影响因子: 6.5
作者:
Dong, Bin;Wu, Minhao;Liu, Jingwen
通讯作者: Liu, Jingwen
1 型血管紧张素 II 受体治疗疫苗在高血压动物中的有效性和安全性
DOI: 10.1161/hypertensionaha.112.201020
发表时间: 2013-02-01
期刊: HYPERTENSION
影响因子: 8.3
作者:
Chen, Xiao;Qiu, Zhihua;Liao, Yuhua
通讯作者: Liao, Yuhua
DOI: 10.1073/pnas.0712064105
发表时间: 2008-02-12
影响因子: 11.1
作者:
Kwon, Hyock Joo;Lagace, Thomas A.;Deisenhofer, Johann
通讯作者: Deisenhofer, Johann